Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial
The Lancet - Early Online Publication, 07/02/2012
Clinical Article
Zinkstok SM et al. – Early administration of intravenous aspirin in patients with acute ischaemic stroke treated with alteplase does not improve outcome at 3 months and increases the risk of SICH. The results of this trial do not support a change of the current guidelines, which advise to start antiplatelet therapy 24 h after alteplase.
Methods- In this multicentre, randomised, open–label trial with blind–endpoint assessment, patients with acute ischaemic stroke treated with alteplase were randomly assigned to 300 mg intravenous aspirin within 90 min after start of alteplase treatment or to no additional treatment.
- In both groups, oral antiplatelet therapy was started 24 h after alteplase treatment.
- The primary endpoint was favourable outcome, defined as a score of 0–2 on the modified Rankin scale at 3 months.
- This trial is registered with the Netherlands Trial Register (NTR822).
- Between July 29, 2008, and April 20, 2011, 642 patients (322 patients aspirin, 320 patients standard treatment) of the targeted 800 patients were enrolled.
- At that time, the trial was terminated prematurely because of an excess of symptomatic intracranial haemorrhage (SICH) and no evidence of benefit in the aspirin group.
- At 3 months, 174 (54•0%) patients in the aspirin group versus 183 (57•2%) patients in the standard treatment group had a favourable outcome (absolute difference –3•2%, 95% CI –10•8 to 4•2; crude relative risk 0•94, 0•82 to 1•09, p=0•42).
- Adjusted odds ratio was 0•91 (95% CI 0•66–1•26, p=0•58). SICH occurred more often in the aspirin group (14 [4•3%] patients) than in the standard treatment group (five [1•6%]; absolute difference 2•8%, 95% CI 0•2–5•4; p=0•04).
- SICH was more often the cause of poor outcome in the aspirin group compared with the standard treatment group (11 vs 1, p=0•006).
